159 related articles for article (PubMed ID: 19823111)
21. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
[TBL] [Abstract][Full Text] [Related]
22. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
Segarra TJ; Fakioglu E; Cheshenko N; Wilson SS; Mesquita PM; Doncel GF; Herold BC
PLoS One; 2011; 6(11):e27675. PubMed ID: 22096611
[TBL] [Abstract][Full Text] [Related]
23. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
[TBL] [Abstract][Full Text] [Related]
24. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
[TBL] [Abstract][Full Text] [Related]
26. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.
Keller MJ; Guzman E; Hazrati E; Kasowitz A; Cheshenko N; Wallenstein S; Cole AL; Cole AM; Profy AT; Wira CR; Hogarty K; Herold BC
AIDS; 2007 Feb; 21(4):467-76. PubMed ID: 17301565
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
[TBL] [Abstract][Full Text] [Related]
28. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.
Jiang YH; Emau P; Cairns JS; Flanary L; Morton WR; McCarthy TD; Tsai CC
AIDS Res Hum Retroviruses; 2005 Mar; 21(3):207-13. PubMed ID: 15795526
[TBL] [Abstract][Full Text] [Related]
29. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.
Keller MJ; Carpenter CA; Lo Y; Einstein MH; Liu C; Fredricks DN; Herold BC
PLoS One; 2012; 7(10):e46901. PubMed ID: 23056520
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.
Nel AM; Smythe SC; Habibi S; Kaptur PE; Romano JW
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):161-9. PubMed ID: 20574411
[TBL] [Abstract][Full Text] [Related]
31. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
[TBL] [Abstract][Full Text] [Related]
32. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety.
Moscicki AB; Kaul R; Ma Y; Scott ME; Daud II; Bukusi EA; Shiboski S; Rebbapragada A; Huibner S; Cohen CR
J Acquir Immune Defic Syndr; 2012 Feb; 59(2):134-40. PubMed ID: 22067666
[TBL] [Abstract][Full Text] [Related]
33. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
[TBL] [Abstract][Full Text] [Related]
34. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
[TBL] [Abstract][Full Text] [Related]
35. Fourteen-day safety and acceptability study of the universal placebo gel.
Schwartz JL; Ballagh SA; Kwok C; Mauck CK; Weiner DH; Rencher WF; Callahan MM
Contraception; 2007 Feb; 75(2):136-41. PubMed ID: 17241844
[TBL] [Abstract][Full Text] [Related]
36. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
[TBL] [Abstract][Full Text] [Related]
37. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.
Jespers VA; Van Roey JM; Beets GI; Buvé AM
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):154-8. PubMed ID: 17106275
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; Smythe SC; McCord K; Mitchnick M; Kaptur PE; Romano J
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1181-90. PubMed ID: 20854207
[TBL] [Abstract][Full Text] [Related]
39. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
Bunge KE; Dezzutti CS; Rohan LC; Hendrix CW; Marzinke MA; Richardson-Harman N; Moncla BJ; Devlin B; Meyn LA; Spiegel HM; Hillier SL
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):498-505. PubMed ID: 26565716
[TBL] [Abstract][Full Text] [Related]
40. Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa.
Carraguard Phase II South Africa Study Team
Contraception; 2010 Dec; 82(6):563-71. PubMed ID: 21074021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
